The patent protects Orthocell’s intellectual property for the preparation of bioscaffolds and tendon stem cells to treat rotator cuff tears. The intellectual property further protects Orthocell’s novel tendon regeneration technology, known as autologous tenocyte implantation.
More articles on devices:
FDA clears Life Spine’s expandable lateral interbody system
SpineGuard revenue drops 6% in 2014 so far: 10 key concepts
SI-BONE receives 13th patent
